Nurix Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Nurix Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Nurix Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Nurix Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Nurix Therapeutics Inc (Nurix Therapeutics) is a clinical-stage biopharmaceutical company that discovers, develops and targets protein degradation medicines for cancer and autoimmune diseases. The company’s pipeline products include bexobrutideg (NX-5948) for chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, B-cell malignancies, and healthy volunteer studies; NX-1607 for immuno-oncology; NX 0479/GS 6791 for rheumatoid arthritis and atopic dermatitis; SAR448272/NX-3911 for type 2 inflammatory diseases and BRAF degrader for solid tumors. Its proprietary DELigase platform, AI-integrated discovery engine, and protein degradation technologies enable the development of degrader-based therapeutics and degrader antibody conjugates. Nurix is headquartered in Brisbane, California, the US.
Headquarters
United States of America
Address
1600 Sierra Point Parkway, Brisbane, California, 94005
Website
www.nurixtx.com
Telephone
1 415 6605320
No of Employees
317
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NRIX (NASD)
Revenue (2024)
$84.0M
54%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-36.6%
(2024 vs 2023)
Market Cap*
$2.8B
Net Profit Margin (2024)
XYZ
11.3%
(2024 vs 2023)
* As of and is in US$
Nurix Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Bexobrutideg (NX-5948): Chronic Lymphocytic Leukemia, B-Cell Malignancies and Non-Hodgkin’s Lymphoma |
| NX-1607: Immuno-Oncology Disorders |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In October, the company announced a second research term extension for an oncology program under its collaboration with Gilead Sciences, extending the research term for one collaboration target by two years in exchange for a one-time fee of US$10.0 million. |
| 2025 | Others | In April, the company licensed an undisclosed program targeting a transcription factor for autoimmune diseases to Sanofi. |
| 2025 | Regulatory Approval | In March, the company received approval from the US Food and Drug Administration for Orphan Drug Designation to bexobrutideg (NX-5948) for the treatment of Waldenström macroglobulinemia (WM). |
Competitor Comparison
| Key Parameters | Nurix Therapeutics Inc | Arvinas Inc | Monte Rosa Therapeutics Inc | C4 Therapeutics Inc | Cleave Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Brisbane | New Haven | Boston | Watertown | San Jose |
| State/Province | California | Connecticut | Massachusetts | Massachusetts | California |
| No. of Employees | 317 | 246 | 173 | 104 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Julia P. Gregory | Chairman | Executive Board | 2024 | 73 |
| Arthur T. Sands, M.D., Ph.D | Chief Executive Officer; Director; President | Executive Board | 2020 | 64 |
| Hans van Houte | Chief Financial Officer | Senior Management | 2020 | 60 |
| Christine Ring, Ph.D. | Chief Compliance Officer; Chief Legal Officer; Secretary | Senior Management | 2020 | 61 |
| Paula G. O’Connor, M.D. | Chief Medical Officer | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer